Floatz logo

Busulfanum

Prolymphocytic Leukemia

Explore 21 assets in Prolymphocytic Leukemia →
Floatz Rating
BB65/100
Confidence
Indicative
v0.2
Sponsor
Center for International Blood and Marrow Transplant Research
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06859424CT.gov
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
—Recruiting———
NCT06001385CT.gov
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
—Active Not Recruiting———
NCT03314974CT.gov
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
—Recruiting———
NCT01629511CT.gov
Allogeneic Stem Cell Transplant for CLL
—Terminated———
NCT00719888CT.gov
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Prolymphocytic Leukemia

AssetSponsorPhaseRating
Busulfanum (this asset)Center for International Blood and Marrow Transplant ResearchP2BB · 65
CyclophosphamideCenter for International Blood and Marrow Transplant ResearchP2BBB
FludarabineCenter for International Blood and Marrow Transplant ResearchP3BB
Cyclosporin AFred Hutchinson Cancer CenterP3BB
NivestimCenter for International Blood and Marrow Transplant ResearchP2BB
TacrolimusCenter for International Blood and Marrow Transplant ResearchP2BB
MelphalanCenter for International Blood and Marrow Transplant ResearchP2BB
RituximabAcerta Pharma BVP2B
IbrutinibFred Hutchinson Cancer CenterP2B

+42 more in the Prolymphocytic Leukemia cohort

Other indications for Busulfanum

IndicationSponsorPhaseRating
Myelodysplastic/Myeloproliferative Neoplasm—P2/3BBB · 76
Graft Versus Host Disease—P4BBB · 74
Disease Related To Hematopoietic Stem Cell Transplant—P3BBB · 74

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Busulfanum in Prolymphocytic Leukemia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 13, 2026.
https://terminal.floatz.ai/assets/busulfanum-prolymphocytic-leukemia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →